Abstract CT013: SWOG S1320: Improved progression-free survival with continuous compared to intermittent dosing with dabrafenib and trametinib in patients with BRAF mutated melanoma
Year: 2020
Type: conference-abstract
Source: Cancer Research
Authors: Alain Algazi, Megan Othus, Adil Daud, Roger Lo, Janice Mehnert, Thach-Giao Truong, Robert Conry, Kari Kendra, Gary Doolittle, Joseph I. Clark, Michael Messino, Dennis F. Moore, Christopher Lao, Bryan A. Faller, Rangaswamy Govindarajan, Amy Harker-Murray, Luke Dreisbach, James Moon, Kenneth Grossman, Antoni Ribas
Institutions: University of California, San Francisco, Fred Hutch Cancer Center, University of California, Los Angeles, Rutgers Cancer Institute, Kaiser Permanente, Kaiser Permanente Vallejo Medical Center, University of Alabama at Birmingham, The Ohio State University, Loyola University Chicago, Cancer Center of Kansas, University of Michigan, Missouri Baptist Medical Center, University of Arkansas at Little Rock, Medical College of Wisconsin, Eisenhower Medical Center, University of Utah
Language: English
Topic: Melanoma and MAPK Pathways
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W3082392222